You are here: Welcome to the MPKB » Welcome to the MPKB » Science behind Marshall Paradigm » Science behind olmesartan (Benicar)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:protocol:olmesartan [11.27.2018] – [Other beneficial effects] sallieqhome:protocol:olmesartan [02.25.2019] – [Kidney disease] sallieq
Line 146: Line 146:
   * act as an antiarrhythmic(({{pubmed>long:16094406}}))   * act as an antiarrhythmic(({{pubmed>long:16094406}}))
   * block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pubmed>long:16534230}}))   * block the production of Angiotensin II, thus improving mortality rates in heart failure patients(({{pubmed>long:16534230}}))
 +  * This study demonstrated that olmesartan reduced angiotensin II and aldosterone levels more effectively than azilsartan, resulting in a stable antihypertensive effect. Olmesartan also had an inhibitory effect on cardiac hypertrophy. Accordingly, it may be effective for patients with increased RAAS activity after cardiac surgery or patients with severe cardiac hypertrophy.  (({{pubmed>long:27086671}})) 
  
 <blockquote>Pharmacotherapy targeting the renin-angiotensin system [the mechanism of the ARBs] is one of the most effective means of reducing hypertension and cardiovascular morbidity.(({{pubmed>long:15531767}})) (({{pubmed>long:17984484}})) <blockquote>Pharmacotherapy targeting the renin-angiotensin system [the mechanism of the ARBs] is one of the most effective means of reducing hypertension and cardiovascular morbidity.(({{pubmed>long:15531767}})) (({{pubmed>long:17984484}}))
Line 169: Line 170:
   * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>long:23154587}}))    * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>long:23154587}})) 
   * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed>long:22149003}}))    * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed>long:22149003}})) 
-  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:3862195}})) +  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}})) 
   * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects  (({{pubmed>long:24842388}}))    * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects  (({{pubmed>long:24842388}})) 
  
home/protocol/olmesartan.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.